CN106962683A - 一种养殖水产品专用营养强化液及其制备方法 - Google Patents
一种养殖水产品专用营养强化液及其制备方法 Download PDFInfo
- Publication number
- CN106962683A CN106962683A CN201710235187.7A CN201710235187A CN106962683A CN 106962683 A CN106962683 A CN 106962683A CN 201710235187 A CN201710235187 A CN 201710235187A CN 106962683 A CN106962683 A CN 106962683A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- special purpose
- emulsifying agent
- product special
- strengthening liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 37
- 238000009360 aquaculture Methods 0.000 title claims abstract description 28
- 244000144974 aquaculture Species 0.000 title claims abstract description 28
- 238000005728 strengthening Methods 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 55
- 229930003231 vitamin Natural products 0.000 claims abstract description 55
- 235000013343 vitamin Nutrition 0.000 claims abstract description 55
- 239000011782 vitamin Substances 0.000 claims abstract description 55
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 38
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 37
- 150000001413 amino acids Chemical class 0.000 claims abstract description 25
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 14
- 239000011707 mineral Substances 0.000 claims abstract description 14
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 9
- 239000003755 preservative agent Substances 0.000 claims abstract description 9
- 230000002335 preservative effect Effects 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 239000000047 product Substances 0.000 claims description 38
- 235000001014 amino acid Nutrition 0.000 claims description 24
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 24
- -1 fatty acid ester Chemical class 0.000 claims description 23
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 21
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- 235000010755 mineral Nutrition 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- 229930182817 methionine Natural products 0.000 claims description 12
- 229960003080 taurine Drugs 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 11
- 235000020958 biotin Nutrition 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
- 239000004473 Threonine Substances 0.000 claims description 10
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 10
- 229960002079 calcium pantothenate Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 229960000367 inositol Drugs 0.000 claims description 10
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 10
- 239000001103 potassium chloride Substances 0.000 claims description 10
- 235000011164 potassium chloride Nutrition 0.000 claims description 10
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000011652 vitamin K3 Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- 229960003512 nicotinic acid Drugs 0.000 claims description 9
- 235000001968 nicotinic acid Nutrition 0.000 claims description 9
- 239000011664 nicotinic acid Substances 0.000 claims description 9
- 229920001983 poloxamer Polymers 0.000 claims description 9
- 239000011691 vitamin B1 Substances 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 239000011647 vitamin D3 Substances 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 239000011716 vitamin B2 Substances 0.000 claims description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- 235000019155 vitamin A Nutrition 0.000 claims description 6
- 239000011719 vitamin A Substances 0.000 claims description 6
- 229940045997 vitamin a Drugs 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- 210000004681 ovum Anatomy 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 210000000936 intestine Anatomy 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 6
- 230000008859 change Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 238000005265 energy consumption Methods 0.000 abstract description 2
- 210000000981 epithelium Anatomy 0.000 abstract description 2
- 230000012010 growth Effects 0.000 description 20
- 241000238557 Decapoda Species 0.000 description 18
- 239000002245 particle Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 244000144972 livestock Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000251468 Actinopterygii Species 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 6
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 6
- 235000010241 potassium sorbate Nutrition 0.000 description 6
- 239000004302 potassium sorbate Substances 0.000 description 6
- 229940069338 potassium sorbate Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 241000927735 Penaeus Species 0.000 description 4
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- DPRNENKPXAZQBI-UHFFFAOYSA-N alpha-Vitamin A Natural products OCC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C DPRNENKPXAZQBI-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000238553 Litopenaeus vannamei Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047623 Vitamin C deficiency Diseases 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004943 gill filament Anatomy 0.000 description 2
- 210000000514 hepatopancreas Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 208000010233 scurvy Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 229920002972 Acrylic fiber Polymers 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001131796 Botaurus stellaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000003241 Fat Embolism Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical group CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002741 methionine derivatives Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000593 microemulsion method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003987 organophosphate pesticide Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
- Y02A40/818—Alternative feeds for fish, e.g. in aquacultures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种养殖水产品专用营养强化液及其制备方法。营养强化液包括下述组分:维生素5%~26%;氨基酸1.5%~13%;矿物质4%~13%;乳化剂5%~35%;助乳化剂1.8%~14%;抑菌防腐剂0.1%~0.8%;余量为纯化水。本发明的养殖水产品专用营养强化液为水包油型纳米乳,稳定性好,在胃肠中可使脂溶性维生素迅速释放,与胃肠道上层粘膜层有良好的接触,通过胃肠道上皮粘膜细胞间质,进入血液循环,从而改变了维生素在体内的生理生化过程,并消除了个体间吸收利用的差异,提高了生物利用度。此外,本发明的制备方法简单易行,不需高压均质、加温、冷却等高能耗过程,生产成本低,适合工业化生产。
Description
技术领域
本发明属于功能性营养品技术领域,具体涉及一种养殖水产品专用营养强化液及其制备方法。
背景技术
维生素是一类结构各异、正常生命活动所必需的小分子有机物。与三大营养物质不同,维生素在代谢过程中产生的能量很小,也不是机体组织结构的组成部分,而主要是构成酶的辅酶或辅基,参与调节物质和能量的代谢。每一种维生素对动物机体都有其特殊的功能,水产动物缺乏任何一种维生素都会引起特定的营养代谢障碍,出现维生素缺乏症,轻者可致生长发育不良、增重缓慢、存活率降低,重者引起高死亡率。
现阶段市场所见维生素多为固体制剂,粉末状或颗粒状,在使用过程中溶解不完全,导致提供的维生素达不到所需的吸收浓度;另外,维生素固体制剂中的脂溶性维生素吸收与脂肪相伴随,必须经由肝脏分泌的胆汁溶解才能透过肠腔内的液体环境而到达肠吸收细胞的表面,但是养殖水产品种是比较低等的品种,肝脏在鱼类上是比较完善,同时有胆囊,而在甲壳类上是肝胰腺,没有胆囊,因此水产动物对脂溶性维生素在固态制剂、粉态制剂中的吸收率是很低的。再者,水产动物可以通过体表和鳃丝对营养物质进行主动吸收。
纳米技术,是二十世纪八十年代末期刚刚诞生并正在崛起的新技术,是当今世界科技发展的三大前沿技术之一。纳米技术在医药领域药剂学方面的应用,产生了纳米给药系统(Nanoparticledrugdeliverysystem,NDDS)。
纳米给药系统包括纳米粒、纳米球、纳米囊、纳米脂质体、纳米乳等给药系统。其中的纳米乳(nanoemulsion),也称微乳(microemulsion),是一个由油、水、表面活性剂、助表面活性剂四组分组成的粒径为10~100nm、液滴多为球形,大小均匀,透明或半透明、具热力学稳定和各向同性、热压灭菌或高速离心稳定不分层的、且制备条件温和等特点。其优点有:它为各向同性的透明液体,热力学稳定,可过滤灭菌,易于保存;通过内核的油相和表面活性剂的烃链两部分的增溶,可极大提高药物的溶解度;物理稳定性好,可提高药物的稳定性,易制备;粘度低,通过体表和鳃丝吸收时不会引起变态反应和脂肪栓塞;表面张力低,易通过胃肠壁的水化层,使药物能直接和胃肠上皮细胞接触,纳米乳粒径小且均匀,药物的分散性好,可增加膜的通透性,从而促进药物的吸收,可提高药物的生物利用度等;对于易水解的药物制成油包水型纳米乳可起到保护作用;还可延长水溶性药物的释药时间;在一定程度上能保护药物在胃肠道内免遭酶解,避免肝、胃肠的首过效应;还可改变某些药物的体内分布,在一定程度上具有降低药物在某些组织、器官的毒副作用,能降低药物的过敏反应;临床用途广泛、可通过口服、外泼等途径给药;还有一定缓释或靶向性等优点。
目前,国内维生素主要剂型为粉剂、片剂、注射剂等传统剂型。传统剂型如粉剂粒径为1um-100um,通常口服给药、有首过效应,对于脂溶性维生素难容,呈粉末状,粒径大,拌料饲喂麻烦,饮水饲喂易堵塞水管,用药量大,生物利用度低。注射剂粒径小于15um,通常注射给药,无首过效应,注射给药应激大,对药物溶解性要求高,注射剂中辅料易引发注射部分疼痛及炎症。以上传统的制剂模式造成畜牧科技应用水平低,消耗量大,成本高,生物利用率低等影响。
与同类产品相比,本发明技术得到的成品纳米乳是乳粒径在1-100nm之间的特殊乳剂,成O/W型纳米乳,可被水稀释,口服、注射(根据注射剂要求生产)、局部给药或水中泼洒饲喂均可,同时解决了难溶性物质如脂溶性维生素溶解性问题,用量更少而效果更显著,具备粒径小,弥散性、渗透性、稳定性好,吸收好,生物利用度高,用量少,消耗率低、制备工艺简便、成本低等优点。
本产品纳米乳的关键技术在于:1)纳米乳的配方,是针对养殖水生动物的特点和需求进行研发;2)对纳米微乳维生素的处方筛选和配比的确定:针对不同多维,筛选出一系列低毒或无毒、无刺激的表面活性剂、助表面活性剂和油相,考虑到使用动物、经济性、安全性等指标,筛选并确定纳米乳的最优处方。3)对纳米自微乳工艺的研究:针对不同的多维,研究其所需的最佳工艺条件,摸索出纳米乳粒径和稳定性的控制关键技术。
发明内容
本发明的目的在于克服上述缺陷,利用纳米乳技术,提供一种养殖水产品专用营养强化液,改善维生素的水溶性、分散性和吸收率,彻底解决脂溶性维生素生物利用度问题,为肝胆(肝胰腺)疾患、体质差以及处于应激状态的养殖水产品提供了一种可高度吸收利用的营养强化液。
本发明所采取的技术方案是:
一种养殖水产品专用营养强化液,以重量百分比计,包括下述组分:维生素5%~26%;氨基酸1.5%~13%;矿物质4%~13%;乳化剂5%~35%;助乳化剂1.8%~14%;抑菌防腐剂0.1%~0.8%;余量为纯化水。
优选的,所述养殖水产品专用营养强化液,以重量百分比计,包括下述组分:维生素8%~23%;氨基酸2%~12%;矿物质4.5%~10%;乳化剂8%~30%;助乳化剂2%~12%;抑菌防腐剂0.1%~0.5%;余量为纯化水。
优选的,所述养殖水产品专用营养强化液,以重量百分比计,包括下述组分:维生素14%~23%;氨基酸3%~10%;矿物质5%~7%;乳化剂20%~30%;助乳化剂5%~7%;抑菌防腐剂0.2%~0.4%;余量为纯化水。
优选的,所述维生素包括脂溶性维生素和水溶性维生素。
维生素是人和动物营养、生长所必需的某些少量有机化合物,对机体的新陈代谢、生长、发育、健康有极重要作用,如果长期缺乏某种维生素,就会引起生理机能障碍而发生某种疾病,因此维生素是养殖水产品专用营养强化液必须的组分。
优选的,所述水溶性维生素包括如下重量百分比的组分:维生素B1 0.2%~0.6%、维生素B2 0.05%~0.6%、维生素B6 0.3%~0.7%、维生素B12 0.01%~0.05%、维生素C 1.5%~5%、维生素K3 0.1%~0.5%、烟酰胺1.5%~4.5%、泛酸钙1.5%~3%、肌醇0.5%~2%、叶酸0.02~0.05%、尼克酸0.1~0.3%和生物素0.001%~0.09%。
优选的,所述脂溶性维生素包括如下重量百分比的组分:维生素A 1.5%~3%、维生素D3 0.5%~1.0%和维生素E 0.6%~1%,维生素A和维生素D3规格为100万IU/g。
其中,VC是鱼和虾类所必需的营养成分之一,与激素合成、矿物质吸收、新陈代谢有密切关系,并且能够增强机体免疫力、预防坏血病、保护微血管、促进伤口愈合。VC在甲壳生长及蛋白质代谢中也起重要的作用。如果鱼类得不到充足的VC供给,引起VC的缺乏,表现为食欲不振,游泳缓慢,生长缓慢,体型畸形等,严重时引起坏血病症状,导致生长不良,免疫力低下等。
VE是水产动物重要的营养物质,其主要功能是消除体内多余的自由基,保护脂溶性细胞膜以及不饱和脂肪酸不被氧化,通过促进和调理免疫细胞的功能来提高动物体的免疫力。
VC和VE协同作用配合可以提高水产动物抗应激的作用。
作为饲料添加剂的维生素K3是主要维生素K源,常以其水溶性甲萘醌亚硫酸氢钠衍生物的形式(MSB)存在。
鱼虾类的VB1缺乏症使神经系统失调和失去平衡,它参与糖的代谢,促进丙酮酸的氧化。水产品缺乏VB2的症状是眼部白内障,它主要参能量代谢,促进生长、呼吸和生殖,抗口唇炎。大多数鱼类缺乏VB6表现对刺激反应过敏和游动异常,几乎所有的鱼类对缺乏VB6都非常敏感,其症状约在3~8周表现出来,它参与蛋白质、氨基酸的代谢。泛酸钙是代谢过程中释放能量作用的辅酶A的组成成分,在脂肪酸代谢等方面起重要作用。鱼类需要生物素的量虽然极微,但是生物素确是不可缺少的成分,缺乏的话表现极为敏感。叶酸的缺乏症状是鳃部苍白,红血球减少,前肾的红血球未成熟及巨型异型红血球的出现。VB12是抗恶性贫血因子。此外,为了保证鱼类的正常生长速度,有必要添加胆碱,它有助于肝脏中磷脂的合成及血浆中脂肪的运输。缺乏肌醇表现为生长缓慢,血浆中胆固醇及中性脂肪的浓度升高,而总磷脂质及其他磷脂质的浓度下降。上述维生素协同作用,共同促进鱼虾等水产动物的健康生长。
优选的,所述氨基酸包括如下重量百分比的组分:蛋氨酸0.1%~0.4%、赖氨酸0.2%~1.5%、苏氨酸0.2%~0.7%、精氨酸0.3%~0.7%、牛磺酸1.5%~4%、丙氨酸0.5%~1%和甘氨酸0.5%~1%。
氨基酸(amino acid)指的是含有氨基和羧基的一类有机化合物的通称,它是生物功能大分子蛋白质的基本组成单位,是构成动物营养所需蛋白质的基本物质,是含有一个碱性氨基和一个酸性羧基的有机化合物。水产饲料中添加限制性氨基酸,能改善氨基酸的平衡程度,使饲料中氨基酸和蛋白质具有最高的营养价值,提高饲料蛋白质的消化利用率。本发明配方中的氨基酸包括蛋氨酸、苏氨酸、赖氨酸、精氨酸、牛磺酸、丙氨酸和甘氨酸。其中赖氨酸对维持水生动物的正常生长、发育和神经系统的正常机能具有非常重要的作用。饲料中缺乏赖氨酸会导致水生动物生长缓慢,还会出现脂肪肝、骨质钙化率降低等症状。蛋氨酸是必须氨基酸中唯一含硫氨基酸,参与水生动物体内甲基的转移和肾上腺素、胆碱、肌醇的合成以及肝脏内磷脂的代谢。蛋氨酸可以合成脱氨酸,而脱氨酸具有保肝解毒功能。因此蛋氨酸能促进水生动物的生长,防止脂肪肝、花肝等疾病的产生。精氨酸可以增加肝脏中精氨酸(arginase)的活性,有助于将血液中的氨转变为尿素而排泄出去,所对高氨血症,肝脏机能障碍等均有功效。牛磺酸主要是从肾脏排泄,肾脏依据膳食中牛磺酸含量调节其排出量,以维持体内牛磺酸含量的相对稳定。甘氨酸和丙氨酸除了补充氮源之外,还有引诱鱼群的特殊作用,还可以提高水产动物的抗病能力,由于不是靠药物而主要靠强化营养提高抗病力,这对保护生态环境和强化绿色食品有着重要现实意义。
优选的,所述乳化剂包括卵磷脂、大豆磷脂、脂肪酸甘油酯、聚氧乙烯失水山梨醇脂肪酸酯、Span系列失水山梨醇脂肪酸酯、Myrij系列聚氧乙烯脂肪酸酯、Brij系列聚氧乙烯脂肪醇醚、EL系列蓖麻油聚氧乙烯醚和泊洛沙姆中的至少一种。
其中:卵磷脂属于一种混合物,是存在于动植物组织以及卵黄之中的一组黄褐色的油脂性物质,其构成成分包括磷酸、胆碱、脂肪酸、甘油、糖脂、甘油三酸酯以及磷脂,卵磷脂被誉为与蛋白质、维生素并列的“第三营养素”。大豆磷脂是一种混合磷脂,它是由磷脂酰胆碱(卵磷脂,简称PC,高等级为PPC)、磷脂酰乙醇胺(脑磷脂,简称PE)、磷脂酰肌醇(肌醇磷脂,简称PI)、磷脂酰丝胺酸(丝胺酸磷脂,简称PS)等成分组成,磷脂是人体细胞(细胞膜、核膜、质体膜)的基本成分,并对神经、生殖、激素等有重要关系,具有很高营养价值和医用价值。
聚氧乙烯失水山梨醇脂肪酸酯,简称聚山梨酯(Polysorbate),也叫吐温型乳化剂,为司盘(Span,山梨醇脂肪酸酯)和环氧乙烷的缩合物,为一类非离子型去污剂,其包括很多种,例如:吐温-60(Tween-60)为硬脂酸酯;吐温-80(Tween-80)为油酸酯;吐温-20(Tween-20)为月桂酸酯,为聚氧乙烯去水山梨醇单月桂酸酯和一部分聚氧乙烯双去水山梨醇单月桂酸酯的混合物。在本发明中优选乳化剂为Tween-80。
失水山梨醇脂肪酸酯(Span系列)是多元醇型表面活性剂,从化学结构上看,这类表面活性剂是多元醇的部分脂肪酸酯,它属于非离子表面活性剂,是一种优良的油包水或水包油型表面活性剂,其中Span-80的乳化性最为优质,在本发明中优选乳化剂为Span-80。
Myrijj系列聚氧乙烯脂肪酸酯具有较强水溶性,乳化能力强,其包括Myrij-45、Myrij-49、Myrij-51、Myrij-52和Myrij-53。
EL系列蓖麻油聚氧乙烯醚具有较强水溶性,包括EL-20、EL-40和EL-80,其中EL-40为水包油型乳化剂,在毛纺工业中作毛油,具有良好的抗静电性,与其他抗静电剂拼混使用效果更佳,本品还用于油墨、制药、农药等行业作乳化剂使用;EL-80可作腈纶、维纶、丙纶等化纤油剂的组分,具有抗静电性和乳化作用,可作有机磷农药乐果的乳化剂,乳液聚合乳化剂,毛油的乳化剂,广泛用于纺织印染、涂料、油墨等行业,还用作各种油品的乳化剂。
泊洛沙姆(Poloxamer)为聚氧乙烯聚氧丙烯醚嵌段共聚物,商品名为普流尼克(Pluronic),其是一类新型的高分子非离子表面活性剂,作为一种水包油乳化剂是目前用于静脉乳剂极少数合成乳化剂之一,用其制备的乳剂,乳粒少,一般在1μm以下,吸收率高,物理性质稳定,在本发明中优选乳化剂为泊洛沙姆。
在本发明中优选乳化剂为Tween80、span80、大豆磷脂和泊洛沙姆中的至少一种。
优选的,所述助乳化剂包括乙醇、丙二醇、丙三醇、乙二醇、正丁醇和聚乙二醇中的至少一种。
其中聚乙二醇由环氧乙烷与水或乙二醇逐步加成聚合而成,相对分子量较低的聚乙二醇可用作溶剂、助溶剂、O/W型乳化剂和稳定剂,助乳化剂可以为聚乙二醇400;丙二醇包括1,2-丙二醇和1,3-丙二醇,1,2-丙二醇可以作为优质的助乳化剂。在本发明中助乳化剂优选1,2-丙二醇、丙三醇和聚乙二醇400中的一种或几种。
优选的,所述抑菌防腐剂为对羟基苯甲酸酯、苄基醇、氯丁醇、苯氧乙醇、苯酚及其衍生物、季铵化合物、苯甲酸、山梨酸或它们的碱性盐中的至少一种。
优选的,所述矿物质包括氯化钾和/或氯化钠,主要用于调节水产动物体内电解质平衡。此外,还可以包含其他对于水产动物有益的矿物质。
优选的,所述矿物质包括如下重量百分比的组分:氯化钾0.7~1.5%和氯化钠3.5~5.0%。
一种养殖水产品专用营养强化液的制备方法,包括下列步骤:
1)量取适量纯化水置于容器内,将乳化剂和助乳化剂加入容器内,缓慢搅拌均匀;
2)向容器内加入水溶性维生素、氨基酸、矿物质、抑菌防腐剂,缓慢搅拌溶解;
3)将脂溶性维生素加入容器,缓慢搅拌10~30min,形成透明澄清液体;
4)加水至1000mL,搅匀即得成品纳米乳;
所述养殖水产品专用营养强化液的组分如上述任一项所述。
本发明的有益效果是:
1、本发明制备的养殖水产品专用营养强化液比传统剂型维生素稳定性好。
2、本发明制备的养殖水产品专用营养强化液为水包油型纳米乳,为各向同性的热力学稳定体系,极大地改善了维生素在水中的溶解性、分散性和透析性能,在胃肠中可使脂溶性维生素迅速释放,与胃肠道上层粘膜层有良好的接触,通过胃肠道上皮粘膜细胞间质,进入血液循环,从而改变了维生素在体内的生理生化过程,并消除了个体间吸收利用的差异,以及在使用维生素进行水体外泼时提高了吸收率,从而提高了生物利用度。
3、与同类产品相比,本发明技术得到的成品纳米乳是乳粒径在1-100nm之间的特殊乳剂,成O/W型纳米乳,可被水稀释,口服、注射(根据注射剂要求生产)、局部给药或水中泼洒饲喂均可,同时解决了难溶性物质如脂溶性维生素溶解性问题,用量更少而效果更显著,具备粒径小,弥散性、渗透性、稳定性好,吸收好,生物利用度高,用量少,消耗率低、制备工艺简便、成本低等优点。
4、本发明所提出的制备方法简单易行,不需高压均质、加温、冷却等高能耗过程,生产成本低,适合工业化生产。
具体实施方式
下面结合具体实施例对本发明作进一步的说明,但并不局限于此。
实施例1
1、量取700mL纯化水置于容器内,选用乳化剂Tween80质量百分比为20%、聚乙二醇400的质量百分比为5%加入容器内,缓慢搅拌均匀;
2、向容器内加入水溶性维生素,(水溶性维生素各组分质量百分比为:维生素B10.2%、维生素B2 0.05%、维生素B6 0.3%、维生素B12 0.01%、维生素C 1.5%、维生素K30.1%、烟酰胺1.5%、泛酸钙1.5%、肌醇0.5%、叶酸0.02%、尼克酸0.1%、生物素0.075%)、氨基酸(氨基酸各组分质量百分比为:蛋氨酸0.1%、赖氨酸0.2%、苏氨酸0.2%、精氨酸0.3%、牛磺酸1.5%、丙氨酸0.5%和甘氨酸0.5%)、山梨酸钾0.3%,缓慢搅拌溶解;
3、向容器中加入氯化钾1.1%,氯化钠4.5%,缓慢搅拌溶解;
4、将脂溶性维生素(脂溶性维生素各组分质量百分比为:维生素A(100万IU/g)2.2%、维生素D3(100万IU/g)0.6%和维生素E 0.8%)加入容器,缓慢搅拌10~30min,形成透明澄清液体;
5、加水至1000mL,搅匀即得成品纳米乳。
实施例2
1、量取700mL纯化水置于容器内,选用乳化剂Tween80质量百分比为25%、聚乙二醇400的质量百分比为6%加入容器内,缓慢搅拌均匀;
2、向容器内加入水溶性维生素,(水溶性维生素各组分质量百分比为:维生素B10.5%、维生素B2 0.4%、维生素B6 0.5%、维生素B12 0.04%、维生素C 3.0%、维生素K30.4%、烟酰胺3.0%、泛酸钙2.4%、肌醇1.8%、叶酸0.03%、尼克酸0.2%和生物素0.075%)、氨基酸(氨基酸各组分质量百分比为:蛋氨酸0.3%、赖氨酸1.2%、苏氨酸0.6%、精氨酸0.6%、牛磺酸3.3%、丙氨酸0.9%和甘氨酸0.7%)、山梨酸钾0.3%,缓慢搅拌溶解;
3、向容器中加入氯化钾1.1%,氯化钠4.5%,缓慢搅拌溶解;
4、将脂溶性维生素(脂溶性维生素各个组分质量百分比为:维生素A(100万IU/g)2.2%、维生素D3(100万IU/g)0.6%和维生素E 0.8%)加入容器,缓慢搅拌10~30min,形成透明澄清液体;
5、加水至1000mL,搅匀即得成品纳米乳。
实施例3
与实施例1的制备方法相同,不同之处在于配方如下:
Tween80质量百分比为20%、聚乙二醇400的质量百分比为6%;维生素B1 0.3%、维生素B2 0.1%、维生素B6 0.4%、维生素B12 0.02%、维生素C 2%、维生素K3 0.2%、烟酰胺2%、泛酸钙1.5%、肌醇0.5%、叶酸0.03%、尼克酸0.2%、生物素0.01%;维生素A2%、维生素D3 0.8%、维生素E 0.8%;蛋氨酸0.2%、赖氨酸0.3%、苏氨酸0.3%、精氨酸0.4%、牛磺酸2%、丙氨酸0.6%、甘氨酸0.7%;氯化钾1.1%、氯化钠4.5%;苯甲酸钠0.3%。
实施例4
与实施例1的制备方法相同,不同之处在于配方如下:
Tween80质量百分比为30%、聚乙二醇400的质量百分比为7%;维生素B1 0.6%、维生素B2 0.6%、维生素B6 0.7%、维生素B12 0.05%、维生素C 5%、维生素K30.5%、烟酰胺4.5%、泛酸钙3.0%、肌醇2.0%、叶酸0.05%、尼克酸0.3%、生物素0.09%;维生素A3.0%、维生素D3 1.0%、维生素E 1.0%;蛋氨酸0.4%、赖氨酸1.5%、苏氨酸0.7%、精氨酸0.7%、牛磺酸4%、丙氨酸0.9%、甘氨酸0.7%;氯化钾1.1%,氯化钠4.5%;山梨酸钾0.3%。
实施例5
与实施例1的制备方法相同,不同之处在于配方如下:
Tween80质量百分比为23%、Span80质量百分比为7%、1,2-丙二醇的质量百分比为6%;维生素B1 0.5%、维生素B2 0.4%、维生素B6 0.5%、维生素B12 0.04%、维生素C3.0%、维生素K3 0.4%、烟酰胺3.0%、泛酸钙2.4%、肌醇1.8%、叶酸0.03%、尼克酸0.2%、生物素0.075%;维生素A2.2%、维生素D3 0.6%、维生素E 0.8%;蛋氨酸0.3%、赖氨酸1.2%、苏氨酸0.6%、精氨酸0.6%、牛磺酸3.3%、丙氨酸0.9%、甘氨酸0.7%;氯化钾1.1%、氯化钠4.5%;山梨酸钾0.3%。
实施例6
与实施例1的制备方法相同,不同之处在于配方如下:
大豆磷脂质量百分比为10%、泊洛沙姆质量百分比为10%,1,2-丙二醇的质量百分比为6%;维生素B1 0.5%、维生素B2 0.4%、维生素B6 0.5%、维生素B12 0.04%、维生素C3.0%、维生素K3 0.4%、烟酰胺3.0%、泛酸钙2.4%、肌醇1.8%、叶酸0.03%、尼克酸0.2%、生物素0.075%;维生素A2.2%、维生素D3 0.6%、维生素E 0.8%;蛋氨酸0.3%、赖氨酸1.2%、苏氨酸0.6%、精氨酸0.6%、牛磺酸3.3%、丙氨酸0.9%、甘氨酸0.7%;氯化钾1.1%、氯化钠4.5%;山梨酸钾0.3%。
实施例7
与实施例1的制备方法相同,不同之处在于配方如下:
大豆磷脂质量百分比为10%、泊洛沙姆质量百分比为10%,丙三醇的质量百分比为6%;维生素B1 0.5%、维生素B2 0.4%、维生素B6 0.5%、维生素B12 0.04%、维生素C3.0%、维生素K3 0.4%、烟酰胺3.0%、泛酸钙2.4%、肌醇1.8%、叶酸0.04%、尼克酸0.2%、生物素0.075%;维生素A2.2%、维生素D3 0.6%、维生素E 0.8%;蛋氨酸0.3%、赖氨酸1.2%、苏氨酸0.6%、精氨酸0.6%、牛磺酸3.3%、丙氨酸0.9%、甘氨酸0.7%;氯化钾1.1%、氯化钠4.5%;山梨酸钾0.3%。
对实施例1-7所得到的纳米乳进行鉴定。
实施例8
一、纳米乳类型鉴别
通过染色法鉴定该纳米乳的类型,染色法是利用油溶性染料苏丹红III和水溶性染料亚甲兰在纳米乳中红色或蓝色的扩散快慢来判断纳米乳的类型。
结果:实施例1~7制得纳米乳中蓝色的扩散速度大于红色的扩散速度,证明该体系为O/W型纳米乳。
二、微观形态观察与粒径测定
用透射电镜检测纳米乳的微观形态,将铜网置于蜡板上,在铜网上滴加一小滴纳米乳,自然晾干,把2%磷钨酸滴在蜡板上,将晾干的铜网倒置于染液上,负染15min,再晾干后上电镜观察,可以看到纳米乳液滴的形态,粒径大小及分布。根据电镜照片上标示的比例尺,进行纳米乳液滴直径测量并进行数据统计,计算出粒径平均值。
结果:实施例1~7制得的纳米乳制剂的乳滴呈圆球型,大小均匀,粒径分布范围窄,粒度在20~30nm的粒子占90%,纳米乳的平均粒径约为25.0±2.0nm,粒径比较均匀。
三、稳定性试验
如纳米乳保持100倍重力加速度离心分离5min而不发生相分离,即可认为是稳定的。
结果:将纳米乳放入高速离心机中,以10000rpm速度离心20min,实施例1~7的体系仍为淡黄色澄清透明均一液体,判定纳米乳为稳定体系。
实施例9
生长性能比较试验
对实施例1~7制得的养殖水产品专用营养强化液做生长性能试验,将实施例1~7制得营养强化液分别编号1#、2#、3#、4#、5#、6#、7#,添加量相同;试验条件:试验在80cm×60cm×100cm长方形玻璃缸进行,试验用水是在天然海水的基础上用淡水或盐卤按试验设计调配,经过沉淀、过滤、消毒后备用,pH为8.6,水温控制在25±2℃,24小时连续充气。南美白对虾直接从虾塘捞取,挑选全长为1.5-1.8cm的大小相近的健康的虾仔随机分配,每缸30尾。采用市售某品牌南美白对虾配合饲料(蛋白质含量在40%左右)饲喂。饲养时间为25d,试验开始和结束,分别测定各缸样品虾的体长和体重。饲养期间每天投喂4次,日投喂量为虾体重的5%-8%,视吃食情况进行调整。每天观察并记录虾的摄食、活动及死亡情况,定期进行吸污、换水和施药防病等工作。营养强化液分别100mL兑水100L,水中泼洒连用5d,每隔一周使用一次,直至实验结束;选择生长比速、存活率、投饵系数作为主要的生长性能指标,并对七组生长性能进行统计分析。试验期间各组南美白对虾数据见表1,如表1所示,其中表1中,生长比速=[终末体长(体重)-初始体长(体重)]/试验周期×100%,存活率=试验结束虾尾数/试验开始虾尾数×100%。投饵系数=投饵量/虾体增重量。
表1
由表1中可以看出,1#~7#的生长比速、存活率和投饵系数,25d均有明显增加,但是2#的生长比速、增重比速和存活率均为实施例中最高的,投饵系数为实施例中最小的,因此相对来说,实施例2为最佳实施例。
对比例10
生长性能比较试验
以实施例2制得的养殖水产品专用营养强化液,与市场上现有的粉状水溶营养添加剂做性能比较,南美白对虾直接从虾塘捞取,挑选60尾全长为1.5-1.8cm的大小相近的健康的虾仔随机分配,每缸30尾。采用市售某品牌南美白对虾配合饲料(蛋白质含量在40%左右)饲喂。饲养时间为25d,试验开始和结束,分别测定各缸样品虾的体长和体重。饲养期间每天投喂4次,日投喂量为虾体重的5%-8%,视吃食情况进行调整。每天观察并记录虾的摄食、活动及死亡情况,定期进行吸污、换水和施药防病等工作。营养强化液分别100mL兑水100L,连用5d,每隔一周使用一次,直至实验结束;选择生长比速、存活率、投饵系数作为主要的生长性能指标,并对两组生长性能组进行统计分析。试验期间各组南美白对虾数据见表2,如表2所示,其中表2中,生长比速=[终末体长(体重)-初始体长(体重)]/试验周期×100%,存活率=试验结束虾尾数/试验开始虾尾数×100%。投饵系数=投饵量/虾体增重量。
表2
(注:其中数字肩标,小写字母相同表示差异不显著P>0.05;小写字母不同表示差异显著,P≤0.05)。
结果表明,投喂相同有效成分种类及剂量的纳米乳营养液和粉状水溶营养添加剂,纳米乳营养液组表现出更加优异的生产性能,其中生长比速、增重比速和存活率是显著增加的(P<0.05),投饵系数同比降低。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种养殖水产品专用营养强化液,其特征在于,以重量百分比计,包括下述组分:维生素5%~26% ;氨基酸1.5%~13% ;矿物质4%~13%;乳化剂5%~35% ;助乳化剂1.8%~14%;抑菌防腐剂0.1%~0.8% ;余量为纯化水。
2.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:以重量百分比计,包括下述组分:维生素8%~23% ;氨基酸2%~12% ;矿物质4.5%~10%;乳化剂8%~30% ;助乳化剂2%~12% ;抑菌防腐剂0.1%~0.5% ;余量为纯化水。
3.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:以重量百分比计,包括下述组分:维生素14%~23% ;氨基酸3%~10% ;矿物质5%~7%;乳化剂20%~30% ;助乳化剂5%~7% ;抑菌防腐剂0.2%~0.4% ;余量为纯化水。
4.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:维生素包括脂溶性维生素和水溶性维生素,其中水溶性维生素包括如下重量百分比的组分:维生素B1 0.2%~0.6%、维生素B2 0.05%~0.6%、维生素B6 0.3%~0.7%、维生素B12 0.01%~0.05%、维生素C1.5%~5%、维生素K3 0.1%~0.5%、烟酰胺1.5%~4.5%、泛酸钙1.5%~3%、肌醇0.5%~2%、叶酸0.02~0.05%、尼克酸0.1~0.3%、生物素0.001%~0.09%。
5.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:维生素包括脂溶性维生素和水溶性维生素,其中脂溶性维生素包括如下重量百分比的组分:维生素A 1.5%~3%、维生素D3 0.5%~1.0%和维生素E 0.6%~1%。
6.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:所述氨基酸包括如下重量百分比的组分:蛋氨酸0.1%~0.4%、赖氨酸0.2%~1.5%、苏氨酸0.2%~0.7%、精氨酸0.3%~0.7%、牛磺酸1.5%~4%、丙氨酸0.5%~1%和甘氨酸0.5%~1%。
7.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:所述乳化剂包括卵磷脂、大豆磷脂、脂肪酸甘油酯、聚氧乙烯失水山梨醇脂肪酸酯、Span系列失水山梨醇脂肪酸酯、Myrij系列聚氧乙烯脂肪酸酯、Brij系列聚氧乙烯脂肪醇醚、EL系列蓖麻油聚氧乙烯醚和泊洛沙姆中的至少一种。
8.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:所述助乳化剂包括乙醇、丙二醇、丙三醇、乙二醇、正丁醇和聚乙二醇中的至少一种。
9.根据权利要求1所述的养殖水产品专用营养强化液,其特征在于:所述矿物质包括如下重量百分比的组分:氯化钾0.7~1.5%和氯化钠3.5~5.0%。
10.一种养殖水产品专用营养强化液的制备方法,其特征在于,包括下列步骤:
1)量取适量纯化水置于容器内,将乳化剂和助乳化剂加入容器内,缓慢搅拌均匀;
2)向容器内加入水溶性维生素、氨基酸、矿物质、抑菌防腐剂,缓慢搅拌溶解;
3)将脂溶性维生素加入容器,缓慢搅拌10~30min,形成透明澄清液体;
4)加水至1000mL,搅匀即得成品纳米乳;
所述养殖水产品专用营养强化液的组分如权利要求1-9任一项所述。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710235187.7A CN106962683A (zh) | 2017-04-12 | 2017-04-12 | 一种养殖水产品专用营养强化液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710235187.7A CN106962683A (zh) | 2017-04-12 | 2017-04-12 | 一种养殖水产品专用营养强化液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106962683A true CN106962683A (zh) | 2017-07-21 |
Family
ID=59337345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710235187.7A Pending CN106962683A (zh) | 2017-04-12 | 2017-04-12 | 一种养殖水产品专用营养强化液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106962683A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111227119A (zh) * | 2020-01-14 | 2020-06-05 | 开封嘉骏生物科技有限公司 | 一种畜禽用复合维生素纳米乳的生产配方及制备方法 |
CN113749197A (zh) * | 2021-10-15 | 2021-12-07 | 江苏福润德科技有限公司 | 一种水产液体预混合饲料 |
CN113966793A (zh) * | 2021-10-29 | 2022-01-25 | 江苏福润德科技有限公司 | 一种粘稠液态水产复合预混料及其生产工艺 |
CN114794330A (zh) * | 2022-04-06 | 2022-07-29 | 诺立(上海)生物工程有限公司 | 一种调节水生动物活力状态的功能性调理剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1124584A (zh) * | 1994-05-19 | 1996-06-19 | 伊沃斯公司 | 生物活性饲料 |
CN103082091A (zh) * | 2013-01-15 | 2013-05-08 | 广州格雷特生物科技有限公司 | 一种畜禽专用营养强化液及其制备方法 |
CN103053828B (zh) * | 2012-12-04 | 2014-01-01 | 广州海因特生物技术有限公司 | 一种减少水产饲料中水溶性维生素溶失的方法 |
CN104304679A (zh) * | 2014-10-27 | 2015-01-28 | 广东金品动物营养有限公司 | 一种复合维生素c、e免疫多糖微乳液制剂及其制备方法和应用 |
-
2017
- 2017-04-12 CN CN201710235187.7A patent/CN106962683A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1124584A (zh) * | 1994-05-19 | 1996-06-19 | 伊沃斯公司 | 生物活性饲料 |
CN103053828B (zh) * | 2012-12-04 | 2014-01-01 | 广州海因特生物技术有限公司 | 一种减少水产饲料中水溶性维生素溶失的方法 |
CN103082091A (zh) * | 2013-01-15 | 2013-05-08 | 广州格雷特生物科技有限公司 | 一种畜禽专用营养强化液及其制备方法 |
CN104304679A (zh) * | 2014-10-27 | 2015-01-28 | 广东金品动物营养有限公司 | 一种复合维生素c、e免疫多糖微乳液制剂及其制备方法和应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111227119A (zh) * | 2020-01-14 | 2020-06-05 | 开封嘉骏生物科技有限公司 | 一种畜禽用复合维生素纳米乳的生产配方及制备方法 |
CN113749197A (zh) * | 2021-10-15 | 2021-12-07 | 江苏福润德科技有限公司 | 一种水产液体预混合饲料 |
CN113966793A (zh) * | 2021-10-29 | 2022-01-25 | 江苏福润德科技有限公司 | 一种粘稠液态水产复合预混料及其生产工艺 |
CN114794330A (zh) * | 2022-04-06 | 2022-07-29 | 诺立(上海)生物工程有限公司 | 一种调节水生动物活力状态的功能性调理剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103082091B (zh) | 一种畜禽专用营养强化液及其制备方法 | |
CN106962683A (zh) | 一种养殖水产品专用营养强化液及其制备方法 | |
HUT54033A (en) | Process for producing pharmaceutical compositions | |
US5169634A (en) | Pharmaceutical dosage form for the medication of fish | |
Dawood et al. | The growth performance, antioxidative capacity, and histological features of intestines, gills, and livers of Nile tilapia reared in different water salinities and fed menthol essential oil | |
CN102133392A (zh) | 促进虾蟹蜕壳硬壳和防病抗应激的水体泼洒复合制剂 | |
CN101530466B (zh) | 一种含有牛至油和维生素的纳米药物 | |
CN104304797B (zh) | 一种畜禽用复合维生素纳米乳的制造工艺 | |
CN100521964C (zh) | 鳝鱼用饲料 | |
Riet-Correa et al. | Spontaneous acute poisoning by Crotalaria retusa in sheep and biological control of this plant with sheep | |
CN103316031B (zh) | 壳寡糖的减肥降脂应用 | |
CN102558391A (zh) | 维生素e琥珀酸酯-壳聚糖接枝物及其制备方法和应用 | |
CN109090580A (zh) | 一种用于肿瘤患者的特定全营养配方食品及其制备方法 | |
CN101982176B (zh) | 兽用复方亚硒酸钠-维生素e口服纳米乳制剂与制备方法 | |
CN102283842A (zh) | 一种复方乙酰甲喹氟苯尼考纳米乳抗菌药物及其制备方法 | |
CN103054833A (zh) | 一种兽用抗菌药物油乳剂微囊包被剂及制备方法 | |
CN102274179A (zh) | 一种乙酰甲喹纳米乳抗菌药物及其制备方法 | |
CN102552293A (zh) | 一种注射用复合维生素亚微乳冻干粉针及其制备方法 | |
Das et al. | Choline chloride induces growth performance of Indian major carps and air-breathing fish species with an outcome of quality food-fish under a semi-intensive culture system: A biochemical investigation | |
CN106071113A (zh) | 一种乳化纳米级维生素预混料及其制备方法 | |
CN110227166A (zh) | 一种肿瘤术中缓释化疗靶向制剂的药物载体及其制备方法 | |
Dzhabrailova et al. | Characterization of Physico-Chemical Parameters and Toxicological Properties of Neocytin | |
CN107041482A (zh) | 一种肉仔鸡专用的纳米复合营养液制剂及其制备方法 | |
CN107115349A (zh) | 一种兽用维生素ade微乳注射液及其制备方法 | |
CN104351219B (zh) | 一种用于水产养殖的复合阿维菌素制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170721 |
|
RJ01 | Rejection of invention patent application after publication |